Herochat

Goldman Sachs analysts ask : Is curing patients a sustainable business model?

Imperial

  • Was once the Greatest of All Time
  • ******
  • 2557
  • +8/-2
    • View Profile
https://arstechnica.com/tech-policy/2018/04/curing-disease-not-a-sustainable-business-model-goldman-sachs-analysts-say/

Analyst report notes that Gilead’s hep C cure will make less than $4 billion this year.

One-shot cures for diseases are not great for business—more specifically, they’re bad for longterm profits—Goldman Sachs analysts noted in an April 10 report for biotech clients, first reported by CNBC.

The investment banks’ report, titled “The Genome Revolution,” asks clients the touchy question: “Is curing patients a sustainable business model?” The answer may be “no,” according to follow-up information provided.

Analyst Salveen Richter and colleagues laid it out:

Quote from: Goldman Sachs
The potential to deliver “one shot cures” is one of the most attractive aspects of gene therapy, genetically engineered cell therapy, and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies... While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.

For a real-world example, they pointed to Gilead Sciences, which markets treatments for hepatitis C that have cure rates exceeding 90 percent. In 2015, the company’s hepatitis C treatment sales peaked at $12.5 billion. But as more people were cured and there were fewer infected individuals to spread the disease, sales began to languish. Goldman Sachs analysts estimate that the treatments will bring in less than $4 billion this year.

Quote from: Goldman Sachs
“[Gilead]’s rapid rise and fall of its hepatitis C franchise highlights one of the dynamics of an effective drug that permanently cures a disease, resulting in a gradual exhaustion of the prevalent pool of patients,” the analysts wrote. The report noted that diseases such as common cancers—where the “incident pool remains stable”—are less risky for business.

...........
Sig : Sierra Skye


Imperial

  • Was once the Greatest of All Time
  • ******
  • 2557
  • +8/-2
    • View Profile
If you still buy into the GOP and corporate Democratic notion of so-called "Free market healthcare" you are either uniformed, a crook, or a willing dupe.
Sig : Sierra Skye


AP

  • ********
  • 17026
  • +89/-52
    • View Profile
This is why I'll be moving to Canada soon.

Panthergod

  • ********
  • 7452
  • +40/-82
    • View Profile
Ethical/Moral insanity of Western culture incarnate.

superlurker

  • ***
  • 508
  • +19/-0
    • View Profile
I wonder what those Goldman Sachs geniuses were paid to come up with that conclusion.

This reminds me of a report some years back about the prospects of the ringtone industry as smart phones were coming around.

Given that the pharmaceutical industry is rather stronger than the ringtone industry was, I expect outcomes may differ, though. At least in the U.S. And if they do, the long-term result will likely be that the U.S. will lose its status as the world leader in health care technology even if market failure will fuck Americans over.

Dlbiininja

  • ******
  • 3236
  • +22/-11010
  • Destroyer of father of socks self-esteem 😂😂😂
    • View Profile
My negative Karma correlates to the amount of butthurt I've caused you! 
blowmeuptom.com/   https://www.facebook.com/tomleykisshow/
http://garyanddino.com/ 

Uhtceare

  • *****
  • 1299
  • +16/-8
    • View Profile
 Wasn't this literally one of the things Lex Luthor did?

Thanos6

  • *****
  • 1482
  • +18/-17
    • View Profile
Wasn't this literally one of the things Lex Luthor did?

That's what I was going to say.
Truten forever!